Purpose

Mechanical thrombectomy devices and stent retrievers have recently been advocated for use as first-line therapy in acute ischemic stroke. Here we evaluate the safety and effectiveness of the CATCH+ stent retriever as a percutaneous thrombectomy device.

Methods

A retrospective analysis was performed on 101 consecutive patients who presented with anterior or posterior intracranial vessel occlusion and were treated with the CATCH+ intracranial system, either alone or in combination with intravenous tissue plasminogen activator, at a single treatment center. The primary outcome measure was successful post-procedural reperfusion as classified by the mTICI score. Secondary endpoints included mortality rate, incidence of adverse events, and functional outcomes evaluated at discharge using the mRS score.

Results

Sixty-nine (68.3%) patients received thrombolysis prior to mechanical thrombectomy. Successful reperfusion (mTICI ≥ 2b) was achieved in 73.3% of patients at the end of the procedure, and good functional outcomes (mRS ≤ 2) were observed in 32.7% of patients at discharge. Three patients developed asymptomatic subarachnoid hemorrhage, two developed asymptomatic dissections of the internal carotid artery, and one patient developed a symptomatic intracranial hemorrhage. Seventeen patients died (mortality rate 16.8%).

Conclusions

The CATCH+ device is a safe and effective mechanical thrombectomy device for the first-line treatment of acute ischemic stroke.

中文翻译：

---

CATCH+ 作为血管重建一线治疗急性缺血性卒中的安全性和有效性

目的

最近提倡将机械取栓装置和支架取栓器用作急性缺血性卒中的一线治疗。在这里，我们评估了 CATCH+ 支架取栓器作为经皮取栓装置的安全性和有效性。

方法

对 101 名出现前或后颅内血管闭塞并在单一治疗中心接受 CATCH+ 颅内系统单独或联合静脉内组织纤溶酶原激活剂治疗的连续患者进行了回顾性分析。主要结果指标是按 mTICI 评分分类的成功的术后再灌注。次要终点包括死亡率、不良事件发生率和出院时使用 mRS 评分评估的功能结果。

结果

69 名 (68.3%) 患者在机械取栓前接受了溶栓治疗。在手术结束时，73.3% 的患者实现了成功的再灌注（mTICI  ≥  2b），并且在 32.7% 的患者出院时观察到了良好的功能结果（mRS  ≤  2）。3 名患者出现无症状蛛网膜下腔出血，2 名患者出现无症状颈内动脉夹层，1 名患者出现症状性颅内出血。17 名患者死亡（死亡率 16.8%）。

结论

CATCH+ 装置是一种安全有效的机械取栓装置，用于急性缺血性卒中的一线治疗。